

ILE 'HOME' ENTERED AT 14:00:52 ON 06 OCT 2004

=> Index bioscience

FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, AQUALINE, ANABSTR, ANTE,
AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS,
BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB,
CROPU, DISSABS, DDFB, DDFU, DGENE, ...' ENTERED AT 14:01:35 ON 06 OCT 2004

74 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view
search error messages that display as 0* with SET DETAIL OFF.

=> s DAKO(25w)erbb2

2 FILE CANCERLIT
1 FILE CAPLUS
2 FILE EMBASE

47 FILES SEARCHED...

1 FILE LIFESCI
11 FILE USPATFULL
1 FILE USPAT2

6 FILES HAVE ONE OR MORE ANSWERS, 74 FILES SEARCHED IN STNINDEX

L1 QUE DAKO(25W) ERBB2

=> file hits

FILE 'USPATFULL' ENTERED AT 14:03:32 ON 06 OCT 2004

CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CANCERLIT' ENTERED AT 14:03:32 ON 06 OCT 2004

FILE 'EMBASE' ENTERED AT 14:03:32 ON 06 OCT 2004

COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'CAPLUS' ENTERED AT 14:03:32 ON 06 OCT 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'LIFESCI' ENTERED AT 14:03:32 ON 06 OCT 2004

COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'USPAT2' ENTERED AT 14:03:32 ON 06 OCT 2004

CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

=> s DAKO(25w)erbb2

L2 18 DAKO(25W) ERBB2

=> dup rem l2

PROCESSING COMPLETED FOR L2

L3 15 DUP REM L2 (3 DUPLICATES REMOVED)

=> d l12 1-15 kwic

L12 NOT FOUND

The L-number entered has not been defined in this session, or it
has been deleted. To see the L-numbers currently defined in this
session, enter DISPLAY HISTORY at an arrow prompt (=>).

=> d l2 1-15 kwic

L2 ANSWER 1 OF 18 USPATFULL on STN

DETD . . . cancer, various diagnostic/prognostic assays are available. In one embodiment, ErbB2 overexpression may be analyzed by IHC, e.g. using the HERCEPTEST® (Dako). Paraffin embedded tissue sections from a tumor biopsy may be subjected to the IHC assay and accorded a **ErbB2** protein staining intensity criteria as follows:

L2 ANSWER 2 OF 18 USPATFULL on STN

DETD . . . samples, even when the samples are subjected to antigen retrieval. The following antibodies were used: anti-CD3 (CALTAG); anti-EGFR; anti-Progesterone Receptor; (Dako); and anti-**erbB2** (Zymed). Following TBST washes, proteins were visualized as described in Example 4.

L2 ANSWER 3 OF 18 USPATFULL on STN

DETD . . . cancer, various diagnostic/prognostic assays are available. In one embodiment, ErbB2 overexpression may be analyzed by IHC, e.g. using the HERCEPTEST® (Dako). Paraffin embedded tissue sections from a tumor biopsy may be subjected to the IHC assay and accorded a **ErbB2** protein staining intensity criteria as follows:

L2 ANSWER 4 OF 18 USPATFULL on STN

DETD . . . various diagnostic/prognostic assays are available. In one embodiment, ErbB2 overexpression may be analyzed by immuno-histochemistry (IHC), e.g. using the HERCEPTEST® (Dako). Paraffin embedded tissue sections from a tumor biopsy may be subjected to the IHC assay and accorded a **ErbB2** protein staining intensity criteria as follows:

Score 0 no staining is observed or membrane staining is observed in less than. . .

L2 ANSWER 5 OF 18 USPATFULL on STN

DETD . . . to the Her2/ErbB2 extracellular domain (ECD) of the naturally occurring Her2/ErbB2 receptor and a synthetic ECD sequence; and 2) a **DAKO** rabbit polyclonal antibody that recognizes the intracellular domain of the Her2/**ErbB2** protein, which is present in naturally occurring forms of the protein but is absent in the synthetic ECD sequence. The. . .

DETD [0146] To detect the **DAKO** rabbit anti-(human Her2/**ErbB2**) antibody, the same procedure was used except that the primary antibody was detected with a biotinylated goat anti-rabbit secondary antibody. . .

L2 ANSWER 6 OF 18 USPATFULL on STN

DETD [0086] Western blot analyses of cell lysates and immunohistochemistry were performed using anti-CD45 panleukocyte (Dako, Glostrup, Denmark), anti-estrogen receptor α (ER α), anti-**erbB2**, and anti-HID-5 (clone 1068-1; designated "Cl 1" in the right panel of FIG. 2A) antibodies as previously described [Krop et. . .

L2 ANSWER 7 OF 18 USPATFULL on STN

DETD . . . cancer, various diagnostic/prognostic assays are available. In one embodiment, ErbB2 overexpression may be analyzed by IHC, e.g. using the HERCEPTEST.TM. (Dako). Paraffin embedded tissue sections from a tumor biopsy may be subjected to the IHC assay and accorded a **ErbB2** protein staining intensity criteria as follows:

L2 ANSWER 8 OF 18 USPATFULL on STN

DETD . . . cancer, various diagnostic/prognostic assays are available. In

one embodiment, ErbB2 overexpression may be analyzed by IHC, e.g. using the HERCEPTEST® (Dako). Paraffin embedded tissue sections from a tumor biopsy may be subjected to the IHC assay and accorded a **ErbB2** protein staining intensity criteria as follows: Score 0, no staining is observed or membrane staining is observed in less than.

L2 ANSWER 9 OF 18 USPTAFULL on STN

DETD . . . cancer, various diagnostic/prognostic assays are available. In one embodiment, ErbB2 overexpression may be analyzed by IHC, e.g. using the HERCEPTEST® (Dako). Paraffin embedded tissue sections from a tumor biopsy may be subjected to the IHC assay and accorded a **ErbB2** protein staining intensity criteria as follows:

L2 ANSWER 10 OF 18 USPTAFULL on STN

DETD . . . fixed for 10 minutes in 4% paraformaldehyde in TBS (Tris-buffered saline). After appropriate blocking steps, a rabbit anti-human cerbB2 antibody (DAKO) was employed at the manufacturers' pre-diluted concentration and an ABC peroxidase system (Vector Labs) was utilized for immunocytochemical detection of cell surface c-**erbB2**-protein.

DETD . . . mouse monoclonal antibody which recognizes an epitope on the proliferating cell antigen Ki-67, in combination with an alkaline phosphate system (APAAP-**DAKO**) was used for immunocytochemical detection of cell proliferation. The experiments described in this Example were performed in parallel with those for detection of cell surface **erbB2** described in Example 3. For further description of the use of the Ki-67 antigen to analyze cell proliferation see Gerdes, . . .

L2 ANSWER 11 OF 18 USPTAFULL on STN

DETD . . . mouse monoclonal antibody which recognizes an epitope on the proliferating cell antigen Ki67, in combination with an alkaline phosphate system (APAAP-**DAKO**) was used for immunocytochemical detection of cell proliferation. The experiments described in this Example were performed in parallel with those for detection of cell surface **erbB2** described in Example 3. For further description of the use of the Ki67 antigen to analyze cell proliferation see Gerdes, . . .

L2 ANSWER 12 OF 18 CANCERLIT on STN

AB . . . Inc., Downers Grove, IL). Additionally, IHC for p185(c-erbB2) was performed in all cases using the Dako polyclonal antibody clone A0485 (Dako Co., Carpinteria, CA). RESULTS: None of the 21 osteosarcomas had evidence of HER-2/neu gene amplification by FISH, whereas p185(c-**erbB2**) IHC was negative in all cases. CONCLUSIONS: HER-2/neu gene amplification appeared to be an uncommon event in pediatric osteosarcomas. The. . .

L2 ANSWER 13 OF 18 CANCERLIT on STN

AB . . . (stage IV = 2). Overaccumulation of p53 and c-erbB2 was detected immunocytochemically on deparaffinized sections using monoclonal antibodies anti-human p53 (Dako Inc) and anti-human c-**erbB2** (Biogenics). Information was obtained in 19/27 tumors from patients with stage I and II disease. p53 positivity was defined as. . .

L2 ANSWER 14 OF 18 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN

AB . . . Inc., Downers Grove, IL). Additionally, IHC for p185(c-erbB2) was performed in all cases using the Dako polyclonal antibody clone A0485 (Dako Co., Carpinteria, CA). RESULTS. None of the 21 osteosarcomas had evidence of HER-2/neu gene amplification by FISH, whereas p185(c-

erbB2) IHC was negative in all cases. CONCLUSIONS. HER-2/neu gene amplification appeared to be an uncommon event in pediatric osteosarcomas. The. . .

L2 ANSWER 15 OF 18 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.
on STN

AB . . . of the lung, surgically resected from May 1995 to November 1996, were immunohistochemically stained with the monoclonal antibodies to p53 (DAKO- p53) and c-**erbB2** (phamingen 15821A) respectively. We compared the expression status of these markers between the normal bronchial mucosa and the tumor tissue,. . .

=> s (erbB2 or Her-2/neu or Apo-1 or p185) (25w)prostate and cancer

'NEU' IS NOT A VALID FIELD CODE

'NEU' IS NOT A VALID FIELD CODE

'NEU' IS NOT A VALID FIELD CODE

'NEU' IS NOT A VALID FIELD CODE

'NEU' IS NOT A VALID FIELD CODE

'NEU' IS NOT A VALID FIELD CODE

L4 179 (ERBB2 OR HER-2/NEU OR APO-1 OR P185) (25W) PROSTATE AND CANCER

=> dup rem l4

PROCESSING COMPLETED FOR L4

L5 142 DUP REM L4 (37 DUPLICATES REMOVED)

=> d 15 125-142 bib ab kwic